Evidence map›Paper›PMID 35798791›Full record

ArticleScientific reports2022

Characterization of regulatory transcriptional mechanisms in hepatocyte lipotoxicity.

Joaquín Pérez-Schindler, Elyzabeth Vargas-Fernández, Bettina Karrer-Cardel, Danilo Ritz, Alexander Schmidt, Christoph Handschin

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 0 citations in OpenAlex.

  1. Review
  2. Spatial genomics: mapping human steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  3. Article
  4. Positive allosteric GABAFrontiers in physiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Joaquín Pérez-SchindlerBiozentrum, University of Basel, 4056, Basel, Switzerland. jperezsc@broadinstitute.org.
Elyzabeth Vargas-FernándezBiozentrum, University of Basel, 4056, Basel, Switzerland.
Bettina Karrer-CardelBiozentrum, University of Basel, 4056, Basel, Switzerland.
Danilo RitzBiozentrum, University of Basel, 4056, Basel, Switzerland.
Alexander SchmidtBiozentrum, University of Basel, 4056, Basel, Switzerland.
Christoph HandschinBiozentrum, University of Basel, 4056, Basel, Switzerland. christoph.handschin@unibas.ch.
University of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease is a continuum of disorders among which non-alcoholic steatohepatitis (NASH) is particularly associated with a negative prognosis. Hepatocyte lipotoxicity is one of the main pathogenic factors of liver fibrosis and NASH. However, the molecular mechanisms regulating this process are poorly understood. The main aim of this study was to dissect transcriptional mechanisms regulated by lipotoxicity in hepatocytes. We achieved this aim by combining transcriptomic, proteomic and chromatin accessibility analyses from human liver and mouse hepatocytes. This integrative approach revealed several transcription factor networks deregulated by NASH and lipotoxicity. To validate these predictions, genetic deletion of the transcription factors MAFK and TCF4 was performed, resulting in hepatocytes that were better protected against saturated fatty acid oversupply. MAFK- and TCF4-regulated gene expression profiles suggest a mitigating effect against cell stress, while promoting cell survival and growth. Moreover, in the context of lipotoxicity, some MAFK and TCF4 target genes were to the corresponding differentially regulated transcripts in human liver fibrosis. Collectively, our findings comprehensively profile the transcriptional response to lipotoxicity in hepatocytes, revealing new molecular insights and providing a valuable resource for future endeavours to tackle the molecular mechanisms of NASH.

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsHepatocytesLiverLiver CirrhosisMiceMice, Inbred C57BLProteomics

Identifiers

PMID35798791
PMCPMC9262951
OpenAlexW3208550315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.